Beyond Air Reports Revenue Growth to $1.76 Million and Improved Net Loss in Latest 10-Q Filing

Beyond Air, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenues of $1.76 million, a substantial increase from $683,000 in the same period last year. This growth is attributed to the expansion of hospital contracts and the initiation of sales in international markets. The cost of revenues for the quarter was $1.6 million, resulting in a gross profit of $156,000, compared to a gross loss of $332,000 in the prior year. The company’s net loss for the quarter was $8.08 million, or $1.53 per share, a notable improvement from a net loss of $13.06 million, or $5.32 per share, in the previous year.

Operationally, Beyond Air has made strides in reducing its operating expenses, which totaled $7.77 million for the quarter, down from $13.25 million a year earlier. This reduction was primarily driven by decreased research and development costs, which fell to $3.09 million from $6.01 million, and lower selling, general, and administrative expenses, which decreased to $4.69 million from $7.24 million. The company has also seen a decrease in interest expenses, contributing to the overall improvement in financial performance.

In terms of strategic developments, Beyond Air has been actively expanding its product offerings and market presence. The company received European CE mark approval for its LungFit PH system in November 2024, which allows for the treatment of pulmonary hypertension in both infants and adults. Additionally, Beyond Air has entered into new distribution agreements in several countries, including France, India, and Japan, and is awaiting further regulatory approvals in Southeast Asia. The company is also progressing with its LungFit PRO system, targeting viral lung infections, and has plans for a pivotal clinical trial for its Nontuberculous Mycobacteria (NTM) treatment.

As of June 30, 2025, Beyond Air reported total assets of $28.11 million, down from $30.06 million at the end of the previous quarter. The company’s cash and cash equivalents increased to $4.98 million from $4.67 million, while marketable securities decreased to $1.49 million from $2.25 million. The company’s liabilities rose to $17.71 million, up from $15.72 million, primarily due to increased accrued expenses and current liabilities. Beyond Air anticipates needing additional funding within the next year to support ongoing operations and product development, as it expects to continue incurring net losses during this period. Management remains optimistic about securing financing to meet its obligations and support its growth strategy.